BIO tripled in three days, is DeSci an old tree blooming anew?
- Core Opinion: Bio Protocol has built a positive flywheel of "staking-early access-governance" by upgrading its narrative from DeSci to AI Agent-driven DeSci (Agentic DeSci), and launching the BioXP system and BioAgent Launchpad. This propelled the BIO token to double in value within three days. However, the team moving tokens to exchanges and the sector's reliance on narrative hype introduce uncertainty for the future.
- Key Elements:
- The BIO token price briefly broke $0.066 on May 3rd, doubling in three days, before retreating to around $0.06. Its market cap currently stands at approximately $127 million, far below the $1.1 billion peak seen earlier this year.
- Narrative upgrade is key: The shift from decentralized science (DeSci) to AI Agent-driven DeSci, introducing the BioXP system for prioritized early access and accumulation of governance voting power (veBIO).
- The ecosystem's early-stage project, PeptAI, launched on May 1st, achieving 5.9x oversubscription in 30 minutes. By May 4th, oversubscription reached 12.7x ($633,000) with over 700 participants, forming a positive cycle of staking BIO → earning BioXP → early access → governance.
- The Biio Protocol ecosystem has raised over $50 million, with a community of approximately 90,000 members. It previously completed a $6.9 million seed round led by Arthur Hayes' Maelstrom Fund.
- On May 3rd, a team multi-sig address transferred 120 million BIO (worth approximately $5.031 million) to exchanges, raising concerns about "pump and dump," though the price impact was minimal.
- The latest project, PEPTAI, has entered the wet lab phase, operating on a model of "AI Agent autonomous decision-making + on-chain information transparency," pushing DeSci towards the tangible business stage of a "replicable drug discovery pipeline."
- Short-term price action remains highly dependent on narrative hype, but the team is targeting the multi-trillion dollar healthcare market, indicating significant ambition.
Original｜Odaily Planet Daily (@OdailyChina)
Author｜Wenser (@wenser 2010 )
In the gradually warming crypto market, the former "DeSci track star" — BIO — has also delivered an impressive performance: Its price broke through $0.066 on May 3, effectively doubling within 3 days. Now, nearly a year and a half after the DeSci (Decentralized Science) hype at the end of 2024, Bio Protocol, once dubbed a "Binance Launchpool project," has embraced the trend of the AI era, championing the slogan "Agent Pays for Science." Whether this is an old tree blooming anew or a pump-and-dump scheme, the answer may soon be revealed.
New vs. Old Narratives of Bio Protocol: From DeSci to Agentic DeSci
Looking at the drivers behind BIO's price increase, in my view, the most crucial factor is its alignment with a new narrative for the AI era — transitioning from decentralized scientific research to AI Agent and agent-driven decentralized scientific research.
This is not only a further refinement of its market positioning but also a key step in injecting new vitality into the Bio Protocol ecosystem. Specifically, Bio Protocol's key actions are as follows:
- BioXP System: Built on the Bio Protocol V2 staking system, the BioXP system allows priority participation in Ignition Sales (new token fundraising), increases allocation quotas, and accumulates veBIO (governance voting). This is the foundational framework for the long-term development of the ecosystem.
- Financial Support: In September last year, Bio Protocol completed a $6.9 million seed round led by Arthur Hayes's Maelstrom Fund, with participation from Mechanism Capital, Animoca Brands, Presto Labs, etc., to advance its AI-driven Launchpad and BioAgents. It previously also received investment from Yzi Labs (formerly Binance Labs). Sufficient funding is essential for sustaining development through market cycles.
- BioAgent Launchpad: This Launchpad platform, built in conjunction with the BioAgents platform, is centered around the concept of "allowing anyone to deploy a DeSci AI agent." The latestIgnition Sale project, PeptAI, went live on May 1 and was oversubscribed by 5.9x within 30 minutes. As of May 4, it was oversubscribed by 12.7x ($633,000, with the token's launch FDV calculated at $1 million and a token price of $0.1). Currently, over 700 participants have joined; the sale lasts for 14 days, ending on May 14 at 9 PM. In terms of token allocation: 20% of the total PEPTAI supply will be airdropped to BIO stakers (veBIO holders, with a 6-month linear release); 5% is offered publicly via the Ignition Sale; those without BioXP can mint or stake BIO to qualify. Thus, through the Ignition Sale mechanism, Bio Protocol has formed a positive feedback loop: "Stake BIO tokens → Earn BioXP points → Participate in project Ignition Sales → Engage in community governance."
According to official data, the Bio ecosystem has now raised over $50 million, with a community of around 90,000 members.
Driven by this new flywheel effect, the BIO token continued its upward trend over just 3 days, surging from around $0.03 to $0.066, before retreating to around $0.06 for now.
Of course, narrative updates and project iterations are one side of the story. On the other side, the active market-making or potential pump-and-dump actions by the Bio Protocol team are another focal point for the market.
Pump-and-Dump or Active Market Making? The Ambition of the Bio Protocol Team
On the morning of May 3, according to monitoring by crypto analyst Ai Yi (@ai_9684xtpa), BIO rose 118% over the past week. That day, the Bio Protocol project team's multi-sig address transferred 120 million BIO to three addresses, of which approximately 80 million were sent to OKX and Binance, valued at about $5.031 million.
On the other hand, Binance had previously announced that it would add trading pairs like BIO/U to its isolated margin platform on April 28, 2026, at 16:00 (UTC+8), fueling BIO's rise on the margin and futures front.
Currently, BIO's market cap stands at approximately $127 million, still far from its peak of around $1.1 billion in early 2025. Moreover, this operation by the Bio Protocol team did not cause significant volatility in BIO's price. Combined with the broader crypto market recovery above the $80,000 mark, BIO's price may continue to rise in the future.
Furthermore, and more importantly, research related to the Bio Protocol ecosystem's latest Ignition Sale project, PEPTAI, has entered the wet lab experimental stage. It operates on a model of "autonomous AI Agent decision-making + on-chain information transparency," to some extent pushing the DeSci track, which was previously more focused on the proof-of-concept stage, into the real business phase of a "reproducible drug discovery pipeline."
From this perspective, the ambition of the Bio Protocol team has never been small. After all, they are targeting a healthcare market track with a trillion-dollar market cap.
Of course, considering the niche nature and regulatory hurdles of the DeSci track, in the short term, BIO's price trajectory for the year will remain highly dependent on concept speculation.
Recommended Reading:
The Light of DeSci? A Deep Dive into Binance Launchpool's Latest Project BIO
